Vanguard Global Advisers’s Dyne Therapeutics DYN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.16M Buy
71,924
+17,787
+33% +$409K ﹤0.01% 1627
2026
Q2
$1.2M Sell
54,137
-2,255
-4% -$41.9K ﹤0.01% 1623
2026
Q1
$1.02M Buy
+56,392
New +$972K ﹤0.01% 1644

Other funds holding DYN

Vanguard Global Advisers's DYN Position: Q3 2026 in Review

Vanguard Global Advisers increased its Dyne Therapeutics (DYN) stake by 33% in Q3 2026, buying an estimated $409K and bringing the position to 71,924 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #1627.

Vanguard Global Advisers first reported a position in DYN in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.2M in Q2 2026. 270 funds tracked by Wall St. Rank hold DYN as of Q3 2026.

  • Vanguard Global Advisers held 71,924 shares of Dyne Therapeutics worth $1.16M as of Q3 2026.
  • Vanguard Global Advisers bought 17,787 Dyne Therapeutics shares in Q3 2026, an estimated $409K.
  • Dyne Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #1627 holding.
  • Vanguard Global Advisers first reported a position in Dyne Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Dyne Therapeutics position peaked at $1.2M in Q2 2026.
  • 270 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.